ReviewEMBO molecular medicine2020
Sepsis therapies: learning from 30 years of failure of translational research to propose new leads.
Review in EMBO molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
208 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- A consensus blood transcriptomic framework for sepsis.Nature medicine · 2025Guideline
- Assessing Monoclonal and Polyclonal Antibodies in Sepsis and Septic Shock: A Systematic Review of Efficacy and Safety.International journal of molecular sciences · 2025Pooled it
- The core role of central nervous system in sepsis-related organ damage.Frontiers in immunology · 2025Pooled it
- Divergent effects of tumor necrosis factor (TNF) in sepsis: a meta-analysis of experimental studies.Critical care (London, England) · 2024Pooled it
- The role of hemoadsorption in cardiac surgery - a systematic review.BMC cardiovascular disorders · 2024Pooled it
- Anti-PD-L1 Therapy Does Not Improve Survival in a Murine Model of Lethal Staphylococcus aureus Pneumonia.The Journal of infectious diseases · 2021Pooled it
- Age-adjusted quick Sequential Organ Failure Assessment score for predicting mortality and disease severity in children with infection: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Trial
- Kidney function as a key driver of the pharmacokinetic response to high-dose L-carnitine in septic shock.Pharmacotherapy · 2023Trial
- Trial
- Clinical characteristics and risk factors associated with ICU-acquired infections in sepsis: A retrospective cohort study.Frontiers in cellular and infection microbiology · 2022Trial
- Indole-3-carboxaldehyde fromGut microbes · 2026Article
- Steatotic liver disease subtypes and risk of hospitalization for sepsis: a nationwide cohort study.Annals of medicine · 2026Article
- Interleukin-39 is a Prognostic Biomarker and Therapy Target for Sepsis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Laboratory-DetectedHealth science reports · 2026Article
- A biomimetic microphysiological system predicts the impact of sepsis therapeutics on neutrophil-endothelial dynamics.Lab on a chip · 2026Article
- Article
- Decoy receptor 3 as a diagnostic marker for sepsis: a meta-analysis.Intensive care medicine experimental · 2026Review
- Low-density neutrophil heterogeneity and spleen tyrosine kinase as therapeutic targets in sepsis.JCI insight · 2026Article
- Critical illness expands a transcriptionally distinct hypometabolic CD8bioRxiv : the preprint server for biology · 2026Article
148 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sepsis has been identified by the World Health Organization (WHO) as a global health priority. There has been a tremendous effort to decipher underlying mechanisms responsible for organ failure and death, and to develop new treatments. Despite saving thousands of animals over the last three decades in multiple preclinical studies, no new effective drug has emerged that has clearly improved patient outcomes. In the present review, we analyze the reasons for this failure, focusing on the inclusion of inappropriate patients and the use of irrelevant animal models. We advocate against repeating the same mistakes and propose changes to the research paradigm. We discuss the long-term consequences of surviving sepsis and, finally, list some putative approaches-both old and new-that could help save lives and improve survivorship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.